Abstract
Background: Chronic use of sennoside laxatives often causes pseudomelanosis coli. A recent study suggested that pseudomelanosis coli is associated with an increased colorectal cancer risk. A single high dose of highly purified senna extract increased proliferation rate and reduced crypt length in the sigmoid colon compared to historical controls. Aims: To evaluate in a controlled study the effects of highly purified senna extract on cell proliferation and crypt length in the entire colon and on p53 and bcl-2 expression. Methods: Addition of a senna extract to colonic lavage was studied in 184 consecutive outpatients. From 32 randomised patients, 15 with sennosides (Sen), 17 without (NSen), biopsies were taken. Proliferative activity was studied in 4 areas of the colon, using 5-bromo-2′-deoxyuridine labelling and immunohistochemistry (labelling index, LI). Expression of p53 and bcl-2 in the sigmoid colon was determined immunohistochemically. Results: Crypts were shorter in Sen than in NSen in the transverse and sigmoid colon. LI was higher in Sen than in NSen in the entire colon. No difference in p53 expression was seen. Bcl-2 expression was higher in both groups when crypts were shorter and/or proliferation was increased. Conclusion: Sennosides induce acute massive cell loss probably by apoptosis, causing shorter crypts, and increased cell proliferation and inhibition of apoptosis to restore cellularity. These effects may reflect the mechanism for the suggested cancer-promoting effect of chronic sennoside use.
Journal Section:
Original Paper: Large Intestine
References
1.
Franz G: The senna drug and its chemistry. Pharmacology 1993;47(suppl 1):2–6.
2.
Steer HW, Colin-Jones DG: Melanosis coli: Studies of the toxic effects of irritant purgatives. J Pathol 1975:115:199–205.
[PubMed]
3.
Siegers CP, von Hertzberg-Lottin E, Otte M, Schneider B: Anthranoid laxative abuse – a risk for colorectal cancer? Gut 1993;34:1099–1101.
[PubMed]
4.
Siegers CP, Siemers J, Baretton G: Sennosides and aloin do not promote dimethylhydrazine-induced colorectal tumors in mice. Pharmacology 1993;47(suppl 1):205–208.
5.
Mereto E, Ghia M, Brambilla G: Evaluation of the potential carcinogenic activity of senna and cascara glycosides for the rat colon. Cancer Lett 1996;101:79–83.
[PubMed]
6.
Westendorf J, Marquardt H, Poginsky B, Dominiak M, Schmidt J, Marquardt H: Genotoxicity of naturally occurring hydroxyanthraquinones. Mutat Res 1990;240:1–12.
7.
Tikkanen L, Matsushima T, Natori S: Mutagenicity of anthraquinones in the Salmonella preincubation test. Mutat Res 1983;116:297–304.
[PubMed]
8.
Mori H, Sugie S, Niwa K, Yoshimi N, Tanaka T, Hirono I: Carcinogenicity of chrysazin in large intestine and liver of mice. Jpn J Cancer Res 1986;77:871–876.
[PubMed]
9.
Risio M, Lipkin M, Candelaresi GL, Bertone A, Coverlizza S, Rossini FP: Correlations between rectal mucosa cell proliferation and the clinical and pathological features of nonfamilial neoplasia of the large intestine. Cancer Res 1991;51:1917–1921.
[PubMed]
10.
Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE: Increased cell division as a cause of human cancer. Cancer Res 1990;50:7415–7421.
[PubMed]
11.
Kleibeuker JH, Cats A, Zwart N, Mulder NH, Hardonk MJ, de Vries EGE: Excessively high cell proliferation in sigmoid colon after an oral purge with anthraquinone glycosides. J Natl Cancer Inst 1995;87:452–453.
[PubMed]
12.
Fireman Z, Rozen P, Fine N, Chetrit A: Reproducibility studies and effects of bowel preparations on measurement of rectal epithelial proliferation. Cancer Lett 1989;45:59–64.
[PubMed]
13.
Walker NI, Bennett RE, Axelsen RA: Melanosis coli, a consequence of anthraquinone-induced apoptosis of colonic epithelial cells. Am J Pathol 1988;31:465–476.
14.
Mengs U, Rudolph RL: Light and electron-microscopic changes in the colon of the guinea pig after treatment with anthranoid and non-anthranoid laxatives. Pharmacology 1993;47(suppl 1):172–177.
15.
Kastan MB, Onykwere O, Sidransky O, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304–6311.
[PubMed]
16.
Lin D, Shields MT, Ullrich SJ, Appella E, Mercer WE: Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proc Natl Acad Sci USA 1992;89:9210–9214.
[PubMed]
17.
Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991;352:345–347.
[PubMed]
18.
Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1–6.
[PubMed]
19.
Wang Y, Szekely L, Okan I, Klein G, Wiman RG: Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma cell line. Oncogene 1993;8:3427–3431.
[PubMed]
20.
Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B: Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995;55:237–241.
[PubMed]
21.
Welberg JWM, De Vries EGE, Hardonk MJ, Mulder NH, Harms G, Grond J, Zwart N, Koudstaal J, De Ley L, Kleibeuker JH: Proliferation rate of colonic mucosa in normal subjects and patients with colonic neoplasms: a refined immunohistochemical method. J Clin Pathol 1990;43:453–456.
[PubMed]
22.
Hockenbery DM, Zutter M, Hickwey W, Nahm M, Korsmeyer SJ: Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991;88:6961–6965.
[PubMed]
23.
Nijs G: Prostaglandins in the mechanism of action of sennosides; PhD thesis, Leuven, K.U. Leuven, Acco, 1993.
24.
Geboes K, Nijs G, Mengs U, Geboes KPJ, van Damme A, de Witte P: Effects of contact laxatives on intestinal and colonic epithelial cell proliferation. Pharmacology 1993;47(suppl 1):187–195.
25.
McNeil NI, Rampton DS, Phil D: Is the rectum usually empty? A quantitative study in subjects with and without diarrhea. Dis Colon Rectum 1981;24:596–599.
[PubMed]
26.
Nijs G, de Witte P, Geboes K, Lemli J: Inluence of rhein anthrone and rhein on small intestine transit rate in rats: Evidence of prostaglandin mediation. Eur J Pharmacol 1992;218:199–203.
[PubMed]
27.
Halter F, Reinhart WH, Koelz HR, Meyrat P, Lentze MJ, Muller O: 16,16-Dimethylprostaglandin E2 stimulates growth and maturation of rat gastric and small-intestinal mucosa. Scand J Gastroenterol 1984;92(suppl):178–183.
28.
Yamaguchi A, Ishida T, Nishimura G, Katoh M, Miyazaki I: Investigation of colonic prostaglandins in carcinogenesis in the rat colon. Dis Colon Rectum 1991;34:572–576.
[PubMed]
29.
Jimenez de Asua L, Clingan D, Rudland PS: Initiation of cell proliferation in cultured mouse fibroblasts by prostaglandin F2a. Proc Natl Acad Sci USA 1975;72:2724–2728.
[PubMed]
30.
Hakeda Y, Harada S, Matsumoto T, Tezuka K, Higashino K, Kodama H, Hashimoto-Goto T, Ogata E, Kumegawa M: Prostaglandin F2a stimulates proliferation of clonal osteoblastic MC3T3-E1 cells by up-regulation of insulin-like growth factor I receptors. J Biol Chem 1991;266:21044–21050.
[PubMed]
31.
Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJA: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;398:1313–1316.
32.
Nugent KP, Farmer KCR, Spigelman AD, Williams CB, Phillips RKS: Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993;80:1618–1619.
[PubMed]
33.
Pasricha PJ, Bedi A, O’Connor K, Rashid A, Akhtar AJ, Zahurak ML, Piantadosi S, Hamilton SR, Giardiello FM: The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1995;109:994–998.
[PubMed]
34.
Shiff SJ, Qiao L, Tsai L-L, Rigas B: Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995;96:491–503.
[PubMed]
35.
Levine AJ: The p53 tumor-suppressor gene. N Engl J Med 1992;326:1350–1352.
[PubMed]
36.
Hockenbery DM, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334–336.
[PubMed]
© 2000 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2000
You do not currently have access to this content.
